Published in Healthcare Mergers, Acquisitions and Ventures Week, April 23rd, 2005
The decision comes on the heels of the earlier announcement by Solvay Pharmaceuticals, the company's worldwide (ex-Japan) exclusive development and marketing partner for cetrorelix, to conduct its upcoming phase III development in endometriosis as a primary indication.
Cetrorelix, AEterna Zentaris' lead drug in the class of LHRH antagonists, has successfully...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.